In this case report, the therapeutic follow-up of a four-year-old, male, castrated Shih Tzu with atopic dermatitis is described. The treatment first consisted of prednisolone (Prednisolone®), followed by oclacitinib (Apoquel®) and afterwards lokivetmab (Cytopoint®). Furthermore, the diagnosis of AD and the different treatment options are discussed. In addition, more information is given about lokivetmab (Cytopoint®), a new therapeutic agent.